Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+/HER2-, node-positive, high-risk, early breast cancer

被引：2
|
作者：
Talwar, Ashna
Deshmukh, Ashish
Trivedi, Meghana
Aparasu, Rajender R.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4364
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4364
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
    Reinisch, Mattea
    Harbeck, Nadia
    Rastogi, Priya
    O'shaughnessy, Joyce
    Boyle, Frances
    Cortes, Javier
    Rugo, Hope S.
    Hamilton, Erika
    Goetz, Matthew P.
    Huang, Chiun-Sheng
    Senkus, Elzbieta
    Trakin, Alexey
    Neven, Patrick
    Huober, Jens
    Ran, Wei
    Andre, Valerie
    Munoz-Fernandez, Maria
    Antonio, Belen San
    Shahir, Ashwin
    Martin, Miguel
    Johnston, Stephen
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 227 - 228
  • [32] Efficacy and safety analysis of Chinese patients in monarchE: Abemaciclib combined with adjuvant endocrine therapy for high risk HR+, HER2-early breast cancer.
    Shao Zhimin
    Zhang, Qingyuan
    Song, Chuan-gui
    Ouyang, Quchang
    Liu, Zhenzhen
    Liu, Qiang
    Feng, Jifeng
    Chiu, Joanne Wing Yan
    Tseng, Ling-Ming
    Qian, Chenxi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Abemaciclib pharmacology and interactions in the treatment of HR+/HER2- breast cancer: a critical review
    Martorana, Federica
    Sano, Maria Vita
    Valerio, Maria Rosaria
    Fogli, Stefano
    Vigneri, Paolo
    Danesi, Romano
    Gebbia, Vittorio
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2024, 15
  • [34] Cost-effectiveness of adjuvant abemaciclib and ribociclib in high-risk, hormone receptor-positive, early breast cancer in India
    Sra, Manraj Singh
    Sasi, Archana
    Batra, Atul
    Bakhshi, Sameer
    Ganguly, Shuvadeep
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Docetaxel in Combination with Doxorubicin and Cyclophosphamide as Adjuvant Treatment for Early Node-Positive Breast Cancer in the USA: A Cost-Effectiveness and Cost-Utility Analysis
    Wolowacz, S. E.
    Seal, B. S.
    Tangirala, M.
    CANCER RESEARCH, 2009, 69 (24) : 622S - 623S
  • [36] Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2-Advanced or Metastatic Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 6 - 15
  • [37] Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective
    Sra, Manraj Singh
    Sasi, Archana
    Batra, Atul
    Bakhshi, Sameer
    Ganguly, Shuvadeep
    JCO GLOBAL ONCOLOGY, 2024, 10
  • [38] Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer From the US and Chinese Perspectives
    Zhang, Yingjie
    Zeng, Xiaohui
    Deng, Haijun
    Ma, Fang
    Peng, Ye
    Yi, Lidan
    Tan, Chongqing
    Peng, Liubao
    CLINICAL THERAPEUTICS, 2019, 41 (06) : 1175 - 1185
  • [39] Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-high-risk early breast cancer
    Paluch-Shimon, S.
    Neven, P.
    Huober, J.
    Cicin, I.
    Jiang, Z.
    Goetz, M. P.
    Shimizu, C.
    Huang, C.
    Wei, R. J.
    Nabinger, S. C.
    Forrester, T.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S151 - S151
  • [40] Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective
    Sra, Manraj Singh
    Sasi, Archana
    Batra, Atul
    Bakhshi, Sameer
    Ganguly, Shuvadeep
    JCO GLOBAL ONCOLOGY, 2024, 10
12345